Toripalimab
Pd-1/Pd-L1 (Programmed Cell Death Protein 1/Death Ligand 1) Inhibitors
Sold as Loqtorzi
- Drug class
- Pd-1/Pd-L1 (Programmed Cell Death Protein 1/Death Ligand 1) Inhibitors
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 4
Overview
Toripalimab is an active pharmaceutical ingredient in the Pd-1/Pd-L1 (Programmed Cell Death Protein 1/Death Ligand 1) Inhibitors group (L01FF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 15, 2026 |
| EU European Union | EMA | 1 | May 7, 2026 |
| CA Canada | Health Canada | 1 | March 4, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
LOQTORZI, in combination with cisplatin and gemcitabine, is indicated for the first line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. LOQTORZI, in combination with cisplatin and paclitaxel, is indicated for the first line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
How to take
EUEuropean Union· EMA
1 product
Uses
LOQTORZI, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. LOQTORZI, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PL608740001 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/006120 · revised May 7, 2026
- [3]Health Canada (DPD) · 02562219 · revised March 4, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.